Cyclacel Pharmaceuticals Company Profile (NASDAQ:CYCC)

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals logo

Cyclacel Pharmaceuticals, Inc. operates in the field of cell cycle biology. The Company has generated various families of anticancer drugs that act on the cell cycle, including nucleoside analogs, cyclin dependent kinase (CDK) inhibitors, polo-like kinase (PLK) inhibitors and Aurora Kinase/vascular endothelial growth factor receptor (AK/VEGFR) inhibitors. Its family of anticancer drugs that act on the cell cycle include sapacitabine, seliciclib and CYC065. Its lead candidate, sapacitabine, is an orally available nucleoside analog. A number of nucleoside drugs, such as gemcitabine and cytarabine, also known as Ara-C, both generic drugs, are in use as conventional chemotherapies. Seliciclib, its lead CDK inhibitor, is an oral inhibitor of CDK2/9 enzymes that are central to the process of cell division and cell cycle control. Its second-generation CDK inhibitor, CYC065, is an inhibitor of CDKs targeting CDK2/9 enzymes with utility in both hematological malignancies and solid tumors.

Industry, Sector and Symbol:

Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Exchange: NASDAQ
Symbol: CYCC
CUSIP:

Key Metrics:

Previous Close: $5.65
50 Day Moving Average: $5.87
200 Day Moving Average: $5.23
52-Week Range: $3.60 - $12.60
Trailing P/E Ratio: N/A
Foreward P/E Ratio: -1.03
P/E Growth: 0.00
Market Cap: $N/A
Beta: 3.51

Profitability:

Net Margins: -745.33%
Return on Equity: -80.37%
Return on Assets: -60.61%

Debt:

Current Ratio: 3.37%
Quick Ratio: 3.37%

Additional Links:

Companies Related to Cyclacel Pharmaceuticals:

Consensus Ratings for Cyclacel Pharmaceuticals (NASDAQ:CYCC) (?)

Ratings Breakdown:	1 Buy Rating
Consensus Rating:	Buy (Score: 3.00)
Consensus Price Target:	$60.00 (961.95% upside)

Analysts' Ratings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Show:

Date	Firm	Action	Rating	Price Target	Details
8/12/2016	HC Wainwright	Reiterated Rating	Buy
12/17/2014	JMP Securities	Downgrade	Outperform -> Market Perform	$108.00

(Data available from 9/27/2014 forward)

Earnings History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
11/10/2016
8/10/2016	Q216		($1.01)			View	Listen
5/11/2016	Q116		($0.09)	$512.00 million	$139.00 million	View	Listen
3/24/2016	Q4	($0.08)	($0.10)			View	Listen
11/12/2015	Q315	($0.09)	($0.08)			View	Listen
8/11/2015	Q215		($0.10)			View	Listen
5/12/2015	Q115	($0.25)	($0.19)			View	Listen
3/24/2015	Q414	($0.26)	($0.20)			View	N/A
11/11/2014	Q314	($0.26)	($0.22)			View	N/A
8/12/2014	Q214	($0.30)	($0.22)			View	N/A
5/13/2014	Q114	($0.26)	($0.25)			View	N/A
3/25/2014	Q413	($0.33)	($0.19)	$0.09 million	$0.30 million	View	N/A
11/12/2013	Q3	($0.31)	($0.31)			View	Listen
8/14/2013	Q2 2013		($0.10)	$0.03 million	$0.26 million	View	N/A
5/13/2013	Q1 2013		($1.18)			View	N/A
11/12/2012	Q312		($0.37)			View	N/A

(Data available from 1/1/2011 forward)

Earnings Estimates for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Current Year EPS Consensus Estimate: $-3.89 EPS
Next Year EPS Consensus Estimate: $-5.48 EPS

Current Dividend Information for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Annual Dividend:	$0.15
Dividend Yield:	2.65%
Payout Ratio:	-2.75% (Based on Trailing 12 Months of Earnings) -3.86% (Based on Current Year Consensus EPS Estimate) -2.74% (Based on Next Year Consensus EPS Estimate)

Dividend History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
6/9/2016	Annual	$0.15		7/13/2016	7/17/2016	8/1/2016

(Data available from 1/1/2013 forward)

Insider Trading History for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 3.80%

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction
11/20/2014	Sam L Barker	Director	Buy	3,100	$3.00	$9,300.00
5/21/2013	Lloyd Sems	Director	Buy	33,333	$3.00	$99,999.00
5/21/2013	Paul Mcbarron	CFO	Buy	12,948	$3.03	$39,232.44
5/21/2013	Spiro George Rombotis	Insider	Buy	100,000	$3.00	$300,000.00

(Data available from 1/1/2013 forward)

Latest Headlines for Cyclacel Pharmaceuticals (NASDAQ:CYCC)

Date	Headline
	What's Cyclacel Pharmaceuticals Inc Downside After Today's Huge Decline? - Post News (NASDAQ:CYCC) www.kentuckypostnews.com - September 26 at 4:42 PM
	Cyclacel Pharmaceuticals Now Covered by Analysts at HC Wainwright (CYCC) - Petro Global News 24 (NASDAQ:CYCC) petroglobalnews24.com - September 23 at 4:21 PM
	Stocks Swings: FMSA Holdings Inc (NYSE:FMSA), Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Oshkosh ... - KC Register (NASDAQ:CYCC) www.kcregister.com - September 21 at 5:02 PM
	Will Cyclacel Pharmaceuticals Inc Go Down Anytime Soon? - Post News (NASDAQ:CYCC) www.kentuckypostnews.com - September 21 at 5:02 PM
	Tang Capital Sees Opportunity in Cyclacel Pharma (CYCC); Starboard Pursues Full Board Change at Depomed (DEPO) (NASDAQ:CYCC) galaxystocks.com - September 18 at 9:12 AM
	CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events (NASDAQ:CYCC) biz.yahoo.com - September 13 at 9:22 AM
	Consensus Analyst Feelings for: Micron Technology, Inc. (NASDAQ:MU) , Cyclacel Pharmaceuticals, Inc. (NASDAQ ... - Wall Street Times (press release) (NASDAQ:CYCC) www.wallstreetnews24.com - September 8 at 4:26 PM
	Cyclacel Pharma (CYCC) Announces Presentation of CYC065, CCT68127 Preclinical Data - StreetInsider.com (NASDAQ:CYCC) www.streetinsider.com - September 6 at 9:25 AM
	7:04 am Cyclacel Pharma announces the presentation of preclinical data demonstrating that both its CYC065 and CCT68127 prolong survival in MYCN-addicted neuroblastoma models (NASDAQ:CYCC) finance.yahoo.com - September 6 at 9:25 AM
	Stock Down in Trading Session: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) - Post News (NASDAQ:CYCC) www.kentuckypostnews.com - September 1 at 9:35 AM
	CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (NASDAQ:CYCC) biz.yahoo.com - August 31 at 9:22 AM
	Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Down But Definitely Not Out (NASDAQ:CYCC) streetregister.com - August 28 at 9:05 AM
	Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Down But Definitely Not Out - Street Register (NASDAQ:CYCC) streetregister.com - August 27 at 9:25 AM
	Notable Active Movers: Resolute Energy Corp (NYSE:REN), Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) - NYSE Journal (press release) (NASDAQ:CYCC) stockznews.com - August 24 at 4:31 PM
	Movers and Shakers In Biotech: Cyclacel Pharmaceuticals Inc (CYCC) and Corium International Inc (CORI) - Insider Monkey (blog) (NASDAQ:CYCC) www.insidermonkey.com - August 24 at 4:31 PM
	Investor's Alert: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC), Threshold Pharmaceuticals, Inc. (NASDAQ:THLD) - Newburg Press (NASDAQ:CYCC) newburghpress.com - August 23 at 9:42 PM
	Cyclacel's Date With Decitabine - Seeking Alpha (NASDAQ:CYCC) seekingalpha.com - August 23 at 4:39 PM
	Another Volatile Session to Start the Week (NASDAQ:CYCC) www.fxstreet.com - August 23 at 8:45 AM
	Movers and Shakers In Biotech: Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) and Corium International Inc (NASDAQ:CORI) (NASDAQ:CYCC) marketexclusive.com - August 22 at 4:37 PM
	Cyclacel Pharmaceuticals Inc (CYCC) Spikes On Tang Capital Stake (NASDAQ:CYCC) www.schaeffersresearch.com - August 22 at 4:37 PM
	Here's Why Cyclacel Pharmaceuticals (CYCC) Stock Is Surging Today (NASDAQ:CYCC) www.thestreet.com - August 22 at 4:37 PM
	Cyclacel Stock Runs on Momentum Rocket Fueled by 'Dumb & Dumber' Optimism (NASDAQ:CYCC) www.thestreet.com - August 22 at 4:37 PM
	Cyclacel Pharmaceuticals Inc (CYCC): Don’t Believe the Hype (NASDAQ:CYCC) investorplace.com - August 22 at 12:58 PM
	Will Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Hit $60 Price Target? - Investor Newswire (NASDAQ:CYCC) www.investornewswire.com - August 21 at 4:19 PM
	Stock Sliding Lower in Trade: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) - Post News (NASDAQ:CYCC) www.kentuckypostnews.com - August 19 at 3:38 PM
	ETF’s with exposure to Cyclacel Pharmaceuticals, Inc. : August 19, 2016 (NASDAQ:CYCC) www.capitalcube.com - August 19 at 3:38 PM
	Cyclacel Pharmaceuticals, Inc.'s (CYCC): Major Stock of Recent Trade - Hot Stocks Point (NASDAQ:CYCC) www.hotstockspoint.com - August 19 at 9:34 AM
	Shares Heading Higher in Session: Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) - Post News (NASDAQ:CYCC) www.kentuckypostnews.com - August 17 at 9:53 PM
	Checklist Stock of the Tuesday - Cyclacel Pharmaceuticals, Inc.'s (CYCC) - Hot Stocks Point (NASDAQ:CYCC) www.hotstockspoint.com - August 17 at 9:53 PM
	CYCLACEL PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report (NASDAQ:CYCC) biz.yahoo.com - August 17 at 4:44 PM
	Turn-Down Day (NASDAQ:CYCC) www.fxstreet.com - August 17 at 9:15 AM
	Why Wall Street Is Bullish On Cyclacel Pharmaceuticals Inc. (NASDAQ: CYCC) - Scibility Media (NASDAQ:CYCC) scibilitymedia.com - August 15 at 10:03 PM
	Cyclacel Pharmaceuticals, Inc.'s (CYCC) CEO Spiro Rombotis on Q2 2016 Results - Earnings Call Transcript (NASDAQ:CYCC) seekingalpha.com - August 10 at 10:44 PM
	Cyclacel Pharmaceuticals, Inc. (CYCC) Updated Price Targets - FTSE News (NASDAQ:CYCC) www.ftsenews.co.uk - August 7 at 9:00 AM
	Cyclacel Pharmaceuticals, Inc. (CYCC) - Financial and Strategic SWOT Analysis Review - New Report Available (NASDAQ:CYCC) www.live-pr.com - August 4 at 4:44 PM
	Cyclacel Pharmaceuticals Inc.: Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results (NASDAQ:CYCC) www.twst.com - August 3 at 4:39 PM
	Cyclacel Pharmaceuticals to Release Second Quarter 2016 Financial Results (NASDAQ:CYCC) www.publicnow.com - August 3 at 9:20 AM
	Cyclacel Pharma (CYCC) Says Preclinical Data Shows CYC065 Demonstrates Promising Activity in Uterine Serous ... - StreetInsider.com (NASDAQ:CYCC) www.streetinsider.com - August 2 at 9:21 AM
	Is $60.024 Price Target Attainable For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)? - Investor Newswire (NASDAQ:CYCC) www.investornewswire.com - July 23 at 4:27 PM
	Strong Sell Calls For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) At 0 - Investor Newswire (NASDAQ:CYCC) www.investornewswire.com - July 17 at 9:06 AM
	Cyclacel Pharmaceuticals Inc (NASDAQ:CYCC) Shifting Institutional Investors Sentiment - Press Telegraph (NASDAQ:CYCC) presstelegraph.com - July 14 at 4:44 PM
	Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) Sellers Increased By 176.26% Their Shorts - Consumer Eagle (NASDAQ:CYCC) www.consumereagle.com - July 14 at 7:16 AM
	Is $60.024 Within Reach For Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC)? - Investor Newswire (NASDAQ:CYCC) www.investornewswire.com - July 11 at 9:20 AM
	Broker Outlook For Cyclacel Pharmaceuticals, Inc. (CYCC) - Fiscal Standard (NASDAQ:CYCC) www.fiscalstandard.com - July 6 at 10:21 PM
	CYCLACEL PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CYCC) biz.yahoo.com - July 6 at 5:02 PM
	Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Expected to Reach Highs Of $60.024 - Investor Newswire (NASDAQ:CYCC) www.investornewswire.com - July 4 at 4:18 PM
	Broker Outlook For The Week Ahead Cyclacel Pharmaceuticals, Inc. (CYCC) - Fiscal Standard (NASDAQ:CYCC) www.fiscalstandard.com - July 4 at 4:18 PM
	Brokers Issue Average Price Target Of 7.00 On Cyclacel Pharmaceuticals, Inc. (CYCC) - Fiscal Standard (NASDAQ:CYCC) www.fiscalstandard.com - July 1 at 10:31 AM
	Cyclacel Pharmaceuticals Incorporated (NASDAQ:CYCC) Shorted Shares Increased By 176.26% - Press Telegraph (NASDAQ:CYCC) presstelegraph.com - June 30 at 10:04 AM
	Cyclacel Pharmaceuticals, Inc. (CYCC) Broker Price Targets For The Coming Week - Fiscal Standard (NASDAQ:CYCC) www.fiscalstandard.com - June 28 at 4:30 PM